Impact of baseline abnormal liver enzymes in the outcome of COVID-19 infection

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
AME PUBLISHING COMPANY
Autores
FARIAS, Joao Pedro
CODES, Liana
VINHAES, Diana
AMORIM, Ana Paula
D'OLIVEIRA, Ricardo Cruz
BITTENCOURT, Paulo Lisboa
Citação
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, v.8, article ID 5, 9p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Little is known about the significance of liver function tests (LFT) abnormalities in COVID-19 and their impact on disease outcomes. The aims of the study were to evaluate abnormalities of LFT in patients with COVID-19 and their impact on disease severity, mortality, and correlation with leukocyte markers of inflammation. Methods: All patients with COVID-19 admitted to the emergency department (ED) of a single reference center were retrospectively evaluated. Data were collected using an electronic medical database covering the following variables: demographics, baseline complete blood count (CBC) and ratios, neutrophillymphocyte (NLR) and monocyte-lymphocyte ratios (MLR), systemic immune-inflammation index (SII), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. Disease severity was defined by the presence of organ failure (OF) or requirement for intensive care unit (ICU) support. Mortality was considered as patient death during hospitalization. Results: A total of 1,539 subjects (799 women, mean age 57 +/- 18 years) with COVID-19 were evaluated. Abnormal AST and/or ALT were seen in 50% of them, with a frequency and magnitude that significantly correlated with leukocyte count and ratios. Both LFT were significantly associated with requirement for hospital and ICU admission and mortality. High AST levels were significantly associated with the presence, number, and types of OFs and in-hospital length of stay (LOS). Elevated ALT was also significantly associated with the aforementioned variables, with the exception of OFs presence, circulatory failure and LOS. Conclusions: LFT abnormalities are frequently seen in COVID-19 patients, reflect SARS-CoV-2 associated inflammation and may predict adverse outcomes. LFT may be useful to aid decision-making in the ED for hospital admission or scheduled outpatient reevaluation.
Palavras-chave
Liver enzymes, COVID-19, mortality
URI
https://observatorio.fm.usp.br/handle/OPI/58874
Referências
  1. Bernsmeier C, 2020, ALIMENT PHARM THER, V52, P855, DOI 10.1111/apt.15932
  2. Bernstein D, 2021, WORLD J GASTROENTERO, V27, P7350, DOI 10.3748/wjg.v27.i42.7350
  3. Bertolini A, 2020, HEPATOLOGY, V72, P1864, DOI 10.1002/hep.31480
  4. Bloom PP, 2021, HEPATOLOGY, V73, P890, DOI 10.1002/hep.31326
  5. Cai QX, 2020, J HEPATOL, V73, P566, DOI 10.1016/j.jhep.2020.04.006
  6. Chen LY, 2020, J DIGEST DIS, V21, P512, DOI 10.1111/1751-2980.12925
  7. Ding ZY, 2021, J HEPATOL, V74, P1295, DOI 10.1016/j.jhep.2020.12.012
  8. Du M, 2022, CLIN RES HEPATOL GAS, V46, DOI 10.1016/j.clinre.2021.101793
  9. Ekpanyapong S, 2022, J VIRAL HEPATITIS, V29, P4, DOI 10.1111/jvh.13590
  10. Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131
  11. Gabrielli M, 2022, VACCINES-BASEL, V10, DOI 10.3390/vaccines10020192
  12. Hu BY, 2021, J MED VIROL, V93, P250, DOI 10.1002/jmv.26232
  13. Hundt MA, 2020, HEPATOLOGY, V72, P1169, DOI 10.1002/hep.31487
  14. Jothimani D, 2020, J HEPATOL, V73, P1231, DOI 10.1016/j.jhep.2020.06.006
  15. Kovalic AJ, 2021, HEPATOLOGY, V73, P1521, DOI 10.1002/hep.31472
  16. Kulkarni AV, 2020, ALIMENT PHARM THER, V52, P584, DOI 10.1111/apt.15916
  17. Leal T, 2021, EUR J GASTROEN HEPAT, V33, P691, DOI 10.1097/MEG.0000000000002152
  18. Lei F, 2020, HEPATOLOGY, V72, P389, DOI 10.1002/hep.31301
  19. Leo M, 2022, DIGEST LIVER DIS, V54, P565, DOI 10.1016/j.dld.2021.12.014
  20. Lowsby R, 2015, EMERG MED J, V32, P531, DOI 10.1136/emermed-2014-204071
  21. McConnell MJ, 2021, J HEPATOL, V75, P647, DOI 10.1016/j.jhep.2021.04.050
  22. Perazzo H, 2017, ANN HEPATOL, V16, P269, DOI 10.5604/16652681.1231586
  23. Phipps MM, 2020, HEPATOLOGY, V72, P807, DOI 10.1002/hep.31404
  24. Pirola CJ, 2020, LIVER INT, V40, P2038, DOI 10.1111/liv.14500
  25. Pozzobon FM, 2021, HEPATOL INT, V15, P493, DOI 10.1007/s12072-021-10141-6
  26. Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044
  27. Qi XL, 2020, J HEPATOL, V73, P455, DOI 10.1016/j.jhep.2020.04.010
  28. Sharma A, 2021, ANN HEPATOL, V21, DOI 10.1016/j.aohep.2020.10.001
  29. Shehab M, 2021, BMJ OPEN GASTROENTER, V8, DOI 10.1136/bmjgast-2020-000571
  30. Siddiqui MA, 2022, DIGEST DIS SCI, V67, P2577, DOI 10.1007/s10620-021-07007-0
  31. Sobotka LA, 2022, DIGEST DIS SCI, V67, P4204, DOI 10.1007/s10620-021-07230-9
  32. Sultan S, 2020, GASTROENTEROLOGY, V159, P320, DOI 10.1053/j.gastro.2020.05.001
  33. Wagner J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89340-y
  34. Weber S, 2021, GUT, V70, P1925, DOI [10.1136/gutjnl-2020-323800, 10.1136/gutjnl-2020-]
  35. Yadav DK, 2021, GUT, V70, P807, DOI 10.1136/gutjnl-2020-322072
  36. Youssef M, 2020, J MED VIROL, V92, P1825, DOI 10.1002/jmv.26055
  37. Yu DD, 2021, VIROL J, V18, DOI 10.1186/s12985-021-01593-1
  38. Zhao WB, 2022, J MED VIROL, V94, P1886, DOI 10.1002/jmv.27627

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - COVID-19